Authorized purpose: Provide semi-automatic, non-invasive bladder-volume measurements from ultrasound data acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; a healthcare professional trained and qualified in ultrasound retains responsibility for the measurements, and the device is indicated for adults only.
Clinical role
Live or post-capture ultrasound measurement assistance with automatic segmentation and dimension measurement, user-editable calipers, and saved bladder-volume results; it is incorporated into the Clarius App and is not standalone software.
Images and patients
Ultrasound · Bladder
Key limitation
Keep in mind: Adult patients only, B-Mode bladder imaging only, and compatible Clarius scanner/transducer and Clarius App workflow required. The user may manually adjust measurements and retains ultimate responsibility under standard practices and clinical judgment; the device does not replace clinical decision-making and is not standalone software.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provide semi-automatic, non-invasive bladder-volume measurements from ultrasound data acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; a healthcare professional trained and qualified in ultrasound retains responsibility for the measurements, and the device is indicated for adults only.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Bladder Input: B-Mode bladder ultrasound data in sagittal and transverse views acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; the labeled patient population is adults, with the product description naming the Clarius C3 HD3 and PA HD3 transducers and iOS/Android Clarius App.
Who uses it?Intended users: Licensed healthcare professionals trained and qualified in ultrasound
What does the software produce?Output: Automatic bladder depth, width, and height/length measurements, automatic sagittal-versus-transverse view detection, calipers displayed on the image, calculated bladder volume, and user-adjustable measurements; the measurement can be saved with the exam.
What is its most important limitation?Key limitation: Adult patients only, B-Mode bladder imaging only, and compatible Clarius scanner/transducer and Clarius App workflow required. The user may manually adjust measurements and retains ultimate responsibility under standard practices and clinical judgment; the device does not replace clinical decision-making and is not standalone software.
Clinical takeaway. Clinical role: Provide semi-automatic, non-invasive bladder-volume measurements from ultrasound data acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; a healthcare professional trained and qualified in ultrasound retains responsibility for the measurements, and the device is indicated for adults only.
Evidence takeaway. Evidence from the reviewed source record: FDA K232257 reports nonclinical verification and validation plus retrospective and prospective clinical performance testing. The retrospective study included 66 subjects aged 31-92, with three expert clinical truthers and a 25% equivalence margin; non-inferiority was reported with p=1.87e-22 and mean difference between percentage differences 0.0548 (95% CI 0.010-0.099). The prospective study included 58 adults aged 21-61, used three qualified reviewers and the same margin, and reported p=1.36e-14 with mean difference -0.0228 (95% CI -0.074-0.028). A clinical validation study confirmed activation, live segmentation, automatic measurements, manual adjustment, and saving results with both scanner types.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provide semi-automatic, non-invasive bladder-volume measurements from ultrasound data acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; a healthcare professional trained and qualified in ultrasound retains responsibility for the measurements, and the device is indicated for adults only.
Live or post-capture ultrasound measurement assistance with automatic segmentation and dimension measurement, user-editable calipers, and saved bladder-volume results; it is incorporated into the Clarius App and is not standalone software.
B-Mode bladder ultrasound data in sagittal and transverse views acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; the labeled patient population is adults, with the product description naming the Clarius C3 HD3 and PA HD3 transducers and iOS/Android Clarius App.
Automatic bladder depth, width, and height/length measurements, automatic sagittal-versus-transverse view detection, calipers displayed on the image, calculated bladder volume, and user-adjustable measurements; the measurement can be saved with the exam.
Adult patients only, B-Mode bladder imaging only, and compatible Clarius scanner/transducer and Clarius App workflow required. The user may manually adjust measurements and retains ultimate responsibility under standard practices and clinical judgment; the device does not replace clinical decision-making and is not standalone software.
FDA K232257 reports nonclinical verification and validation plus retrospective and prospective clinical performance testing. The retrospective study included 66 subjects aged 31-92, with three expert clinical truthers and a 25% equivalence margin; non-inferiority was reported with p=1.87e-22 and mean difference between percentage differences 0.0548 (95% CI 0.010-0.099). The prospective study included 58 adults aged 21-61, used three qualified reviewers and the same margin, and reported p=1.36e-14 with mean difference -0.0228 (95% CI -0.074-0.028). A clinical validation study confirmed activation, live segmentation, automatic measurements, manual adjustment, and saving results with both scanner types.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K232257 reports nonclinical verification and validation plus retrospective and prospective clinical performance testing. The retrospective study included 66 subjects aged 31-92, with three expert clinical truthers and a 25% equivalence margin; non-inferiority was reported with p=1.87e-22 and mean difference between percentage differences 0.0548 (95% CI 0.010-0.099). The prospective study included 58 adults aged 21-61, used three qualified reviewers and the same margin, and reported p=1.36e-14 with mean difference -0.0228 (95% CI -0.074-0.028). A clinical validation study confirmed activation, live segmentation, automatic measurements, manual adjustment, and saving results with both scanner types.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Clarius Bladder AI regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K232257
Samplen=66
IndependenceIndependence not established
K232257
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232257. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: B-Mode bladder ultrasound data in sagittal and transverse views acquired by the Clarius Ultrasound Scanner using curvilinear or phased-array scanners; the labeled patient population is adults, with the product description naming the Clarius C3 HD3 and PA HD3 transducers and iOS/Android Clarius App.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA packet establishes incorporation into the Clarius App on iOS and Android, with app support stated as two versions prior to the latest stable release and use with the specified Clarius scanner/transducers. It does not establish DICOM, PACS, RIS, EHR, interface versions, or a current deployment configuration.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Automatic bladder depth, width, and height/length measurements, automatic sagittal-versus-transverse view detection, calipers displayed on the image, calculated bladder volume, and user-adjustable measurements; the measurement can be saved with the exam.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatic bladder depth, width, and height/length measurements, automatic sagittal-versus-transverse view detection, calipers displayed on the image, calculated bladder volume, and user-adjustable measurements; the measurement can be saved with the exam.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The FDA packet establishes incorporation into the Clarius App on iOS and Android, with app support stated as two versions prior to the latest stable release and use with the specified Clarius scanner/transducers. It does not establish DICOM, PACS, RIS, EHR, interface versions, or a current deployment configuration.
Clarius's support article on cloud data security says Clarius Cloud data is stored in AWS data centers in a customer-chosen region (Canada, United States Oregon, EU Frankfurt or Australia), exams can be sent to PACS by DICOM with cloud storage disabled, activity logs are kept for six months, patient information is stored for seven years, backups run hourly and are kept 365 days, and an independent third party validates security. No certification is named, and the information security whitepaper it cites was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Clarius' cloud security support article states 6-month log retention, 7-year patient data retention, and hourly backups kept for 365 days for its AWS-hosted cloud, with third-party security validation.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The article names Clarius' cloud generally and does not scope these commitments to any specific product release; exact-release scope is not established. These are logging, retention and backup commitments; the article states no alerting or response-time SLAs.
ACR AI Central provides an exact-submission model card for Clarius Bladder AI; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K232257 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Views, quantifies, and reports noninvasive bladder-volume measurements from Butterfly ultrasound systems to support physician diagnosis.
Authorized purpose: BladderScan Prime PLUS is a diagnostic ultrasound system with a bladder indication for noninvasive measurement of urine volume in the bladder using the supported probe and device configuration.
Authorized purpose: EdgeFlow UW20 is a wearable ultrasound system for noninvasive periodic bladder-volume measurement in adults with BMI no greater than 30.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.